A clinical trial to evaluate creatine kinase levels in newborns
Not Applicable
- Registration Number
- CTRI/2022/04/041821
- Lead Sponsor
- Department of Pediatrics
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All consecutive neonates born after 37 weeks of gestation with birth weight more than 2.5 kgs.
Exclusion Criteria
1. Newborns who have received blood transfusion before collection of dried blood spot.
2. Newborns who have isolated congenital heart defects.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method CK-MM levels in newborns as assessed by neonatal CK-MM kit.Timepoint: 1 month
- Secondary Outcome Measures
Name Time Method Prevalence of Duchenne Muscular Dystrophy in newborns with raised CK-MM levelsTimepoint: 1 year;Proportion of various causes responsible for raised neonatal CK-MM levelsTimepoint: 1 year